UBS Group
ASMB icon

UBS Group’s Assembly Biosciences ASMB Stock Holding History

UBS Group’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.1K Sell
364
-9,415
-96% -$269K ﹤0.01% 8385
2025
Q4 		$333K Sell
9,779
-5,984
-38% -$193K ﹤0.01% 6299
2025
Q3 		$404K Buy
15,763
+12,830
+437% +$282K ﹤0.01% 6241
2025
Q2 		$53.1K Buy
2,933
+2,166
+282% +$28.6K ﹤0.01% 7717
2025
Q1 		$7.33K Sell
767
-5,780
-88% -$75.6K ﹤0.01% 8835
2024
Q4 		$103K Buy
6,547
+5,246
+403% +$84.4K ﹤0.01% 6853
2024
Q3 		$19.7K Sell
1,301
-1,648
-56% -$25.1K ﹤0.01% 7385
2024
Q2 		$40.5K Sell
2,949
-286
-9% -$4.08K ﹤0.01% 6852
2024
Q1 		$43K Buy
3,235
+1,221
+61% +$14.2K ﹤0.01% 6580
2023
Q4 		$19.8K Buy
+2,014
New +$19.1K ﹤0.01% 7107
2023
Q2 		– Sell
-883
Closed -$8.9K – 8885
2023
Q1 		$8.9K Sell
883
-1,118
-56% -$18.9K ﹤0.01% 7683
2022
Q4 		$31.2K Buy
2,001
+1,048
+110% +$17.9K ﹤0.01% 7200
2022
Q3 		$19K Buy
953
+902
+1,769% +$21.8K ﹤0.01% 7449
2022
Q2 		$1K Sell
51
-261
-84% -$6.01K ﹤0.01% 9813
2022
Q1 		$8K Sell
312
-215
-41% -$4.62K ﹤0.01% 8652
2021
Q4 		$15K Sell
527
-11,442
-96% -$375K ﹤0.01% 8231
2021
Q3 		$500K Buy
11,969
+123
+1% +$5.16K ﹤0.01% 4739
2021
Q2 		$552K Buy
11,846
+10,547
+812% +$523K ﹤0.01% 4646
2021
Q1 		$72K Buy
1,299
+673
+108% +$44.6K ﹤0.01% 6207
2020
Q4 		$45K Buy
626
+218
+53% +$25.6K ﹤0.01% 6278
2020
Q3 		$81K Sell
408
-130
-24% -$32.7K ﹤0.01% 5298
2020
Q2 		$150K Sell
538
-632
-54% -$147K ﹤0.01% 5006
2020
Q1 		$208K Sell
1,170
-1,012
-46% -$217K ﹤0.01% 4691
2019
Q4 		$536K Buy
2,182
+739
+51% +$136K ﹤0.01% 4784
2019
Q3 		$170K Buy
1,443
+1,017
+239% +$154K ﹤0.01% 5368
2019
Q2 		$69K Buy
+426
New +$81K ﹤0.01% 5647
2019
Q1 		– Sell
-136
Closed -$37K – 7715
2018
Q4 		$37K Sell
136
-68
-33% -$19.7K ﹤0.01% 6326
2018
Q3 		$91K Buy
204
+195
+2,167% +$91.3K ﹤0.01% 5666
2018
Q2 		$4K Buy
+9
New +$4.76K ﹤0.01% 7529
2018
Q1 		– Sell
-81
Closed -$44K – 7794
2017
Q4 		$44K Sell
81
-45
-36% -$20.4K ﹤0.01% 5933
2017
Q3 		$53K Buy
126
+51
+68% +$15.6K ﹤0.01% 5753
2017
Q2 		$19K Sell
75
-49
-40% -$13.8K ﹤0.01% 6330
2017
Q1 		$38K Buy
124
+36
+41% +$8.83K ﹤0.01% 5712
2016
Q4 		$13K Buy
+88
New +$13.1K ﹤0.01% 6758
2016
Q3 		– Sell
-66
Closed -$4K – 7653
2016
Q2 		$4K Buy
+66
New +$4.33K ﹤0.01% 7209
2016
Q1 		– Sell
-28
Closed -$3K – 7615
2015
Q4 		$3K Buy
+28
New +$3.05K ﹤0.01% 7861
2015
Q3 		– Sell
-167
Closed -$39K – 8390
2015
Q2 		$39K Buy
+167
New +$32.2K ﹤0.01% 6213
2015
Q1 		– Sell
-56
Closed -$5K – 8780
2014
Q4 		$5K Buy
+56
New +$5.52K ﹤0.01% 8944

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

UBS Group's ASMB Position: Q1 2026 in Review

UBS Group reduced its Assembly Biosciences (ASMB) stake by 96% in Q1 2026, selling an estimated $269K and leaving 364 shares worth $10.1K. The position accounts for ﹤0.01% of the portfolio, ranked #8385.

UBS Group first reported a position in ASMB in Q4 2014 and has held it in 38 quarters since. The position peaked at $552K in Q2 2021. 75 funds tracked by Wall St. Rank hold ASMB as of Q1 2026.

  • UBS Group held 364 shares of Assembly Biosciences worth $10.1K as of Q1 2026.
  • UBS Group sold 9,415 Assembly Biosciences shares in Q1 2026, an estimated $269K.
  • Assembly Biosciences made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8385 holding.
  • UBS Group first reported a position in Assembly Biosciences in Q4 2014 and has held it in 38 quarters since.
  • UBS Group's Assembly Biosciences position peaked at $552K in Q2 2021.
  • 75 funds tracked by Wall St. Rank held Assembly Biosciences as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.